Literature DB >> 29262275

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Mark Yarchoan1, Alexander Hopkins1, Elizabeth M Jaffee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29262275      PMCID： PMC6549688          DOI： 10.1056/NEJMc1713444

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  906 in total

1.  Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?

Authors:  Wolfram C M Dempke; Klaus Fenchel; Stephen P Dale
Journal:  Transl Lung Cancer Res       Date:  2018-09

2.  Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Authors:  Franziska Eckert; Philipp Schaedle; Daniel Zips; Barbara Schmid-Horch; Hans-Georg Rammensee; Cihan Gani; Cécile Gouttefangeas
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 3.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 4.  Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.

Authors:  Francesca Fenizia; Raffaella Pasquale; Cristin Roma; Francesca Bergantino; Alessia Iannaccone; Nicola Normanno
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 5.  Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Authors:  Lizza E Hendriks; Etienne Rouleau; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 6.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

7.  Perspectives in Radiomics for Personalized Medicine and Theranostics.

Authors:  Seunggyun Ha
Journal:  Nucl Med Mol Imaging       Date:  2019-01-23

Review 8.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

Review 9.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

10.  Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

Authors:  James R Patrinely; Laura X Baker; Elizabeth J Davis; Haocan Song; Fei Ye; Douglas B Johnson
Journal:  Cancer       Date:  2020-05-28       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.